Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect

Earlier reports suggest a link between mitochondrial dysfunction and development of hepatic insulin resistance. Here we used a murine model heterozygous (HET) for a mitochondrial trifunctional protein (MTP) gene defect to determine if a primary defect in mitochondrial long‐chain fatty acid oxidation disrupts hepatic insulin action. Hyperinsulinemic‐euglycemic clamps and signaling studies were performed for assessment of whole‐body and hepatic insulin resistance/signaling. In addition, hepatic fatty acid oxidation and hepatic insulin action were assessed in vitro using primary hepatocytes isolated from HET and wildtype (WT) mice. In both hepatic mitochondria and isolated primary hepatocytes, heterozygosity of MTP caused an ∼50% reduction in mitochondrial fatty acid oxidation, a significantly impaired glucose disposal during the insulin clamp, and a markedly lower insulin‐stimulated suppression of hepatic glucose production. HET mice also exhibited impaired insulin signaling, with increased hepatic phosphorylation of IRS2 (ser731) and reduced Akt phosphorylation (ser473) in both hepatic tissue and isolated primary hepatocytes. Assessment of insulin‐stimulated FOXO1/phospho‐FOXO1 protein content and PEPCK/G6Pase messenger RNA (mRNA) expression did not reveal differences between HET and WT mice. However, insulin‐induced phosphorylation of GSK3β was significantly blunted in HET mice. Hepatic insulin resistance was associated with an increased methylation status of the catalytic subunit of protein phosphatase 2A (PP2A‐C), but was not associated with differences in hepatic diacylglycerol content, activated protein kinase C‐ϵ (PKC‐ϵ), inhibitor κB kinase β (IKK‐β), c‐Jun N‐terminal kinase (JNK), or phospho‐JNK protein contents. Surprisingly, hepatic ceramides were significantly lower in the HET mice compared with WT. Conclusion: A primary defect in mitochondrial fatty acid β‐oxidation causes hepatic insulin resistance selective to hepatic glycogen metabolism that is associated with elevated methylated PP2A‐C, but independent of other mechanisms commonly considered responsible for insulin resistance. (HEPATOLOGY 2013;)

[1]  M. Danson,et al.  Citrate synthase. , 2020, Current topics in cellular regulation.

[2]  F. Booth,et al.  PGC-1α overexpression results in increased hepatic fatty acid oxidation with reduced triacylglycerol accumulation and secretion. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[3]  G. Shulman,et al.  Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. , 2012, Cell metabolism.

[4]  Robert V Farese,et al.  The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. , 2012, Cell metabolism.

[5]  E. Nishimura,et al.  Free Fatty Acid-Induced PP2A Hyperactivity Selectively Impairs Hepatic Insulin Action on Glucose Metabolism , 2011, PloS one.

[6]  S. Summers,et al.  Ceramides as modulators of cellular and whole-body metabolism. , 2011, The Journal of clinical investigation.

[7]  Xianlin Han,et al.  Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease , 2011, Proceedings of the National Academy of Sciences.

[8]  C. Kahn,et al.  PKCδ regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans. , 2011, The Journal of clinical investigation.

[9]  G. Shulman,et al.  Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2 , 2011, Proceedings of the National Academy of Sciences.

[10]  F. Booth,et al.  Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[11]  Sarah Hummasti,et al.  Endoplasmic Reticulum Stress and Inflammation in Obesity and Diabetes , 2010, Circulation research.

[12]  B. Neuschwander‐Tetri.  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.

[13]  F. Booth,et al.  Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. , 2010, Journal of Hepatology.

[14]  M. Patti,et al.  The role of mitochondria in the pathogenesis of type 2 diabetes. , 2010, Endocrine reviews.

[15]  G. Perseghin.  Viewpoints on the Way to a Consensus Session , 2009, Diabetes Care.

[16]  Nathan R. Qi,et al.  Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury , 2009, The Journal of physiology.

[17]  R. Rector,et al.  Mitochondrial trifunctional protein defects: clinical implications and therapeutic approaches. , 2008, Advanced drug delivery reviews.

[18]  F. Booth,et al.  Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long‐Evans Tokushima Fatty (OLETF) rats , 2008, The Journal of physiology.

[19]  M. Birnbaum,et al.  The role of FoxO in the regulation of metabolism , 2008, Oncogene.

[20]  J. Girard,et al.  Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. , 2008, The Journal of clinical investigation.

[21]  F. Booth,et al.  Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[22]  J. Goldstein,et al.  Selective versus total insulin resistance: a pathogenic paradox. , 2008, Cell metabolism.

[23]  R. Rector,et al.  Non-alcoholic fatty liver disease and the metabolic syndrome: an update. , 2008, World journal of gastroenterology.

[24]  G. Shulman,et al.  Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance , 2007, Proceedings of the National Academy of Sciences.

[25]  J. Yates,et al.  Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. , 2007, Nature.

[26]  I. Leclercq,et al.  Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. , 2007, Journal of hepatology.

[27]  G. Shulman,et al.  Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease , 2007 .

[28]  A. Fukamizu,et al.  Nutrient control of phosphorylation and translocation of Foxo1 in C57BL/6 and db/db mice. , 2006, International journal of molecular medicine.

[29]  Michael Roden,et al.  Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[30]  O. McGuinness,et al.  Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. , 2006, Diabetes.

[31]  K. Gumireddy,et al.  Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. , 2005, Diabetes.

[32]  J. Cline,et al.  Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. , 2005, Gastroenterology.

[33]  D. Muoio,et al.  Subsarcolemmal and intermyofibrillar mitochondria play distinct roles in regulating skeletal muscle fatty acid metabolism. , 2005, American journal of physiology. Cell physiology.

[34]  J. Girard,et al.  Role of the liver in the control of carbohydrate and lipid homeostasis. , 2004, Diabetes & metabolism.

[35]  A. Diehl,et al.  Hepatic steatosis and type 2 diabetes mellitus , 2002, Current diabetes reports.

[36]  John Turk,et al.  Characterization of ceramides by low energy collisional-activated dissociation tandem mass spectrometry with negative-ion electrospray ionization , 2002, Journal of the American Society for Mass Spectrometry.

[37]  C. Guguen-Guillouzo.  Isolation and Culture of Animal and Human Hepatocytes , 2002 .

[38]  S. Kliewer,et al.  Peroxisome Proliferator-Activated Receptor-α Regulates Fatty Acid Utilization in Primary Human Skeletal Muscle Cells , 2002 .

[39]  J. Ibdah,et al.  Lack of mitochondrial trifunctional protein in mice causes neonatal hypoglycemia and sudden death. , 2001, The Journal of clinical investigation.

[40]  G. Dohm,et al.  Protein kinase C modulates insulin action in human skeletal muscle. , 2000, American journal of physiology. Endocrinology and metabolism.

[41]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[42]  A. Munnich,et al.  Human trifunctional protein deficiency: a new disorder of mitochondrial fatty acid beta-oxidation. , 1992, Biochemical and biophysical research communications.

[43]  D. Pette,et al.  Metabolic differentiation of distinct muscle types at the level of enzymatic organization. , 1969, European journal of biochemistry.

[44]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[45]  J. Steyaert,et al.  PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. , 2008, International journal of oncology.

[46]  G. Shulman,et al.  Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. , 2007, The Journal of clinical investigation.

[47]  S. Kliewer,et al.  Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. , 2002, Diabetes.

[48]  P. Srere,et al.  [1] Citrate synthase. [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)] , 1969 .